Theravance Q4 2019 Earnings Report

Reported financial results for the fourth quarter and full year ended December 31, 2019.

Key Takeaways

Theravance Biopharma reported fourth-quarter revenue of $29.5 million and full-year revenue of $73.4 million. The company's cash, cash equivalents, and marketable securities totaled $285.8 million as of December 31, 2019.

Successfully launched YUPELRI with Mylan.

Advanced development- and research-stage pipeline, further building a diversified portfolio with promising, differentiated programs in every stage of development.

Partnerships continued to strengthen, with ongoing successful collaborations with Mylan for YUPELRI and Janssen for TD-1473 and TD-5202.

Entered into a new agreement with Pfizer to out-license our skin-selective pan-JAK inhibitor program.

Total Revenue

$29.5M

Previous year: $15.7M

+87.4%

EPS

-$1.17

Previous year: -$0.92

+27.2%

Gross Profit

-$37.5M